These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12411968)

  • 1. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity.
    Wyndaele JJ; Van Dromme SA
    Spinal Cord; 2002 Nov; 40(11):599-600. PubMed ID: 12411968
    [No Abstract]   [Full Text] [Related]  

  • 2. Pilot study evaluating the safety of intradetrusor injections of botulinum toxin type A: investigation of generalized spread using single-fiber EMG.
    Schnitzler A; Genet F; Durand MC; Roche N; Bensmail D; Chartier-Kastler E; Denys P
    Neurourol Urodyn; 2011 Nov; 30(8):1533-7. PubMed ID: 21661038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.
    Akbar M; Abel R; Seyler TM; Bedke J; Haferkamp A; Gerner HJ; Möhring K
    BJU Int; 2007 Sep; 100(3):639-45. PubMed ID: 17532858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
    Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Malavaud B; Marque P; Rischmann P; Gamé X
    Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study.
    Krhut J; Samal V; Nemec D; Zvara P
    Spinal Cord; 2012 Dec; 50(12):904-7. PubMed ID: 22801191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011.
    Kanai A; Zabbarova I; Oefelein M; Radziszewski P; Ikeda Y; Andersson KE
    Neurourol Urodyn; 2012 Mar; 31(3):300-8. PubMed ID: 22275187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
    Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
    J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions.
    Klaphajone J; Kitisomprayoonkul W; Sriplakit S
    Arch Phys Med Rehabil; 2005 Nov; 86(11):2114-8. PubMed ID: 16271557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated Botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele.
    Horst M; Weber DM; Bodmer C; Gobet R
    Neurourol Urodyn; 2011 Nov; 30(8):1546-9. PubMed ID: 21674597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
    Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
    Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions.
    Kuo HC
    Urology; 2006 Feb; 67(2):232-6. PubMed ID: 16442605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
    Gamé X; Castel-Lacanal E; Bentaleb Y; Thiry-Escudié I; De Boissezon X; Malavaud B; Marque P; Rischmann P
    Eur Urol; 2008 Mar; 53(3):613-8. PubMed ID: 17804150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries.
    Kuo HC; Liu SH
    Neurourol Urodyn; 2011 Nov; 30(8):1541-5. PubMed ID: 21717505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder.
    Haferkamp A; Schurch B; Reitz A; Krengel U; Grosse J; Kramer G; Schumacher S; Bastian PJ; Büttner R; Müller SC; Stöhrer M
    Eur Urol; 2004 Dec; 46(6):784-91. PubMed ID: 15548448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lantox treatment of neurogenic dysfunction of the bladder].
    Maksimov VA; Saliukov RV; Martov AG; Borisik VI; Saliukova IuR
    Urologiia; 2010; (5):53-6. PubMed ID: 21254642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
    Abdel-Meguid TA
    J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin use in the lower urinary tract.
    Morrisroe SN; Chancellor MB
    ScientificWorldJournal; 2007 Mar; 7():808-17. PubMed ID: 17619764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of botulinum toxin type a in the bladder wall of children with neurogenic bladder dysfunction: a comparison of histological features before and after injections.
    Pascali MP; Mosiello G; Boldrini R; Salsano ML; Castelli E; De Gennaro M
    J Urol; 2011 Jun; 185(6 Suppl):2552-7. PubMed ID: 21527192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.
    Goessaert AS; Everaert KC
    Expert Rev Neurother; 2012 Jul; 12(7):763-75. PubMed ID: 22853784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases.
    Do Ngoc Thanh C; Audry G; Forin V
    J Pediatr Urol; 2009 Dec; 5(6):430-6. PubMed ID: 19577520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.